Source: VIP Gloves
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • VIP Gloves (VIP) receives Australian Therapeutic Goods Administration (TGA) approval for its nitrile gloves
  • The TGA has registered VIP’s nitrile examination and treatment gloves as a class one medical device and has given approval to sell the gloves in Australia
  • This news follows USA Food and Drug Administration and European Union CE Mark approvals
  • VIP is up 7.50 per cent and is trading at 4.3 cents per share at 2:25 pm AEST

VIP Gloves (VIP) has received Australian Therapeutic Goods Administration (TGA) approval for its nitrile gloves.

Nitrile gloves are a synthetic rubber compound as opposed to latex.

The TGA has registered VIP’s nitrile examination and treatment gloves as a class one medical device and has given approval to sell the gloves in Australia.

This news follows USA Food and Drug Administration and European Union CE Mark approvals.

Chairman Joe Wong is pleased to have secured TGA approval.

“We have been advancing distribution agreements for the Australian
market in recent months and, with TGA accreditation now received, these
can be finalised enabling sales to commence in the coming months,” Dr Wong said.

“VIP Gloves continues to expand its international sales footprint to become
a global glove supplier, providing a platform to launch the company’s house
brands as capacity expands in the coming months when the additional two
production lines come online.”

VIP was up 7.50 per cent and was trading at 4.3 cents per share at 2:25 pm AEST.

VIP by the numbers
More From The Market Online
A patient being dosed with Imugene Limited testing materials.

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic
Image of a woman holding a bottle of hemp oil

Little Green Pharma jumps into distribution with acquisition

Little Green Pharma is aiming to make the strategic acquisition of HH (Australia) Pty Ltd to…
Image of cancer cells

Radiopharm approved to start Lu-RAD202 safety trials, door open for in-human studies

Radiopharm Theranostics has received ethics approval for its trial into Lu-RAD202, a novel treatment for these…
Close up of a nasal spray

LTR Pharma pairs with Men’s Health Downunder for supply of erectile dysfunction spray

LTR Pharma Ltd has signed an agreement with Men's Health Downunder to facilitate supply of its…